Asbestos-Related Diseases and Blood Biomarkers

Asbestos-related Diseases Pub Date : 2019-10-09 DOI:10.5772/intechopen.89438

A. Franko, V. Dolžan, K. Goričar, M. Fikfak

{"title":"Asbestos-Related Diseases and Blood Biomarkers","authors":"A. Franko, V. Dolžan, K. Goričar, M. Fikfak","doi":"10.5772/intechopen.89438","DOIUrl":null,"url":null,"abstract":"Asbestos-related diseases, including asbestosis, benign pleural diseases, lung cancer, other types of cancer, and especially malignant mesothelioma (MM), still represent an enormous problem all over the world and are among the most investigated occupational diseases. Considering that MM is a highly aggressive and severe malignant cancer of pleura, peritoneum and other serosal surfaces, new blood biomarkers for earlier diagnosis, following response to treatment and disease progression, have been intensively investigated. Several studies suggested that soluble mesothelin-related peptides, fibulin-3, survivin, osteopontin, vimentin, calretinin, and many others could be helpful in diagnosis, detecting the progression of MM and evaluating tumour response to treatment; however, these biomarkers have not been validated in clinical practice. Therefore, search for novel better stand-alone or composite biomarkers is under way. The aim of this chapter is to present the importance of blood biomarkers in evaluating the risk of developing asbestos-related diseases, early diagnosis, following the response to treatment and progression of these diseases, with special emphasis on MM.","PeriodicalId":136471,"journal":{"name":"Asbestos-related Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asbestos-related Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.89438","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Asbestos-related diseases, including asbestosis, benign pleural diseases, lung cancer, other types of cancer, and especially malignant mesothelioma (MM), still represent an enormous problem all over the world and are among the most investigated occupational diseases. Considering that MM is a highly aggressive and severe malignant cancer of pleura, peritoneum and other serosal surfaces, new blood biomarkers for earlier diagnosis, following response to treatment and disease progression, have been intensively investigated. Several studies suggested that soluble mesothelin-related peptides, fibulin-3, survivin, osteopontin, vimentin, calretinin, and many others could be helpful in diagnosis, detecting the progression of MM and evaluating tumour response to treatment; however, these biomarkers have not been validated in clinical practice. Therefore, search for novel better stand-alone or composite biomarkers is under way. The aim of this chapter is to present the importance of blood biomarkers in evaluating the risk of developing asbestos-related diseases, early diagnosis, following the response to treatment and progression of these diseases, with special emphasis on MM.

查看原文本刊更多论文

石棉相关疾病和血液生物标志物

与石棉有关的疾病，包括石棉肺、良性胸膜疾病、肺癌、其他类型的癌症，特别是恶性间皮瘤(MM)，仍然是世界各地的一个巨大问题，也是调查最多的职业病之一。考虑到MM是胸膜、腹膜和其他浆膜表面的一种高度侵袭性和严重的恶性肿瘤，新的血液生物标志物在治疗反应和疾病进展后的早期诊断已经被深入研究。一些研究表明，可溶性间皮素相关肽、纤维蛋白-3、生存素、骨桥蛋白、静脉蛋白、calretinin和许多其他蛋白可以帮助诊断、检测MM的进展和评估肿瘤对治疗的反应;然而，这些生物标志物尚未在临床实践中得到验证。因此，寻找新的更好的独立或复合生物标志物正在进行中。本章的目的是介绍血液生物标志物在评估石棉相关疾病的风险、早期诊断、对这些疾病的治疗反应和进展方面的重要性，特别强调MM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asbestos-related Diseases

自引率

0.00%

发文量